Interventional treatments for stroke prevention in atrial fibrillation with emphasis upon the WATCHMAN device

Current Opinion in Neurology

Volumn 21, Issue 1, 2008, Pages 64-69

  Möbius Winkler, Sven ^a   Schuler, Gerhard C ^a   Sick, Peter B ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Institut für Labormedizin   (Germany)

Author keywords

Atrial fibrillation; Left atrial appendage; Stroke; WATCHMAN device

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

ALTERNATIVE MEDICINE; ANTICOAGULANT THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEVICE; DRUG WITHDRAWAL; FEASIBILITY STUDY; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HIGH RISK PATIENT; HUMAN; IMPLANTATION; INTERVENTION STUDY; LONG TERM CARE; MORBIDITY; PERICARDIAL EFFUSION; PLAATO DEVICE; PREVALENCE; REVIEW; RISK REDUCTION; SAFETY; SURGICAL EQUIPMENT; THROMBOEMBOLISM; THROMBUS; WATCHMAN DEVICE;

ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; HEART CATHETERIZATION; HUMANS; PROSTHESES AND IMPLANTS; PROSTHESIS DESIGN; STROKE;

EID: 37849008158     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3282f419b6     Document Type: Review

References (32)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.
2. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74:236-241.
3. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114:257-354.
4. The Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 159:1449-1457.
5. Aguilar M, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007; 3:CD006186. Metaanalysis showing the advantage of long-term warfarin therapy compared to aspirin in patients with nonvalvular atrial fibrillation.
6. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527-539.
7. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; i: 175-179.
8. Ferro D, Loffredo L, Polimeri L, et al. Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2007; 2:24-28. Demonstrates the underuse of warfarin in atrial fibrillation patients eligible for anticoagulant therapy.
9. Stafford R, Singer D. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97:1231-1233.
10. Al Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart 1999; 82:547-555.
11. Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006; 151:956-961.
12. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23:961-969.
13. Hwang JJ, Ko FN, Li YH, et al. Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation. Cardiology 1994; 85:69-75.
14. Pop GA, Meeder HJ, Roelandt JR, et al. Transthoracic echo/Doppler in the identification of patients with chronic nonvalvular atrial fibrillation at risk for thromboembolic events. Eur Heart J 1994; 15:1545-1551.
15. Li YH, Lai LP, Shyu KG, et al. Clinical implications of left atrial appendage flow patterns in nonrheumatic atrial fibrillation. Chest 1994; 105:748-752.
16. Mitusch R, Lange V, Stierle U, et al. Transesophageal echocardiographic determinants of embolism in nonrheumatic atrial fibrillation. Int J Card Imaging 1995; 11:27-34.
17. Black IW, Chesterman CN, Hopkins AP, et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993; 21:451-457.
18. Veinot JP, Harrity PJ, Gentile F, et al. Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination. Circulation 1997; 96:3112-3115.
19. Ernst G, Stöllberger C, Abzieher F, et al. Morphology of the left atrial appendage. Anat Rec 1995; 242:553-561.
20. Bayard YL, Ostermayer SH, Sievert H, et al. Transcatheter occlusion of the left atrial appendage for stroke prevention. Expert Rev Cardiovasc Ther 2005; 3:1003-1008.
21. Garcia-Fernandez MA, Perez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003; 42:1153-1158.
22. Almahameed ST, Khan M, Zuzek RW. Left atrial appendage exclusion and the risk of thromboembolic events following mitral valve surgery. J Cardiovasc Electrophysiol 2007; 18:1-3.
23. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150:288-293.
24. Katz ES, Tsiamtsiouris T, Applebaum RM, et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol 2000; 36:468-471.
25. Nakai T, Lesh MD, Gerstenfeld EP, et al. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation 2002; 105:2217-2222.
26. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002; 105:1887-1889.
27. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO System) to prevent stroke in high-risk patients with nonrheumatic atrial fibrillation. J Am Coll Cardiol 2005; 46:9-14.
28. El-Chami MF, Grow P, Eilen D, et al. Clinical outcomes three years after PLAATO implantation. Catheter Cardiovasc Interv 2007; 69:704-707.
29. Meier B, Palacios I, Windecker S, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003; 60:417-422.
30. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007; 49:1490-1495. First experience with the WATCHMAN device demonstrating safety and feasibility.
31. Onalan O, Lashevsky I, Hamad A, et al. Nonpharmacologic stroke prevention in atrial fibrillation. Exp Rev Cardiovasc Ther 2005; 3:619-633.
32. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119:S108-S121.